J. V. Ravetch

This study shows that combining IL-15 with CD40 agonist antibodies improves anti-tumor immunity in bladder cancer by enhancing T cell responses and memory.

This paper presents the X-ray structure of a nanobody that binds afucosylated IgG1 Fc and disrupts pathogenic interactions, rescuing mice in a dengue model.

This study shows that anti-DENV IgG antibodies drive dengue pathogenesis via FcγRIIIa on splenic macrophages, leading to inflammation and mortality.

This paper introduces antibody-lectin chimeras (AbLecs) as a new immunotherapy approach that blocks glyco-immune checkpoints, enhancing cancer immune responses and synergizing with existing checkpoint inhibitors.

This study evaluates the in vivo protective efficacy of SARS-CoV-2 monoclonal antibodies, finding that in vitro potency does not always predict in vivo activity and that effector function and combinations are critical for protection.

This paper describes engineered ACE2 receptor traps that potently neutralize SARS-CoV-2 by blocking viral entry through enhanced binding affinity.

This study shows that FcRn, not FcγRs, is responsible for maternal-fetal transport of IgG antibodies, suggesting FcRn engineering could improve antibody transfer to the fetus.

This study shows that two Fc-modified monoclonal antibodies limit fetal neurologic damage and vertical transmission of ZIKV in pregnant macaques.